How Often Should MCTD Patients Get PFTs and Echocardiograms?
At a Glance
People with MCTD do not all need lung function tests and echocardiograms on the same schedule. Baseline testing is often considered at diagnosis; annual or more frequent monitoring may be needed with scleroderma-like features or lung disease, while stable, lower-risk patients may be tested less often.
In this answer
4 sections
How often you need lung tests (Pulmonary Function Tests, or PFTs) and echocardiograms depends heavily on your specific symptoms, the exact features of your Mixed Connective Tissue Disease (MCTD), and whether you already have lung or heart involvement. There is no one-size-fits-all “annual” or “biennial” rule for every person with MCTD [1]. If your MCTD includes features of systemic sclerosis (scleroderma) or if you have established lung disease, you will likely need testing annually or even more frequently [2][3]. If your disease is stable and lacks these high-risk features, your doctor will personalize your schedule based on your overall risk profile rather than following a strict calendar [3][1].
What Are These Tests and What Are They Looking For?
When your rheumatologist or pulmonologist orders these tests, they are screening for two of the most critical, yet sometimes “silent,” complications of MCTD:
Interstitial Lung Disease (ILD)
ILD involves inflammation or scarring (fibrosis) in the lung tissue. To screen for and monitor ILD, doctors use:
- Pulmonary Function Tests (PFTs): This involves forcefully blowing into a specialized tube. PFTs measure Forced Vital Capacity (FVC)—the amount of air you can forcefully exhale after taking a deep breath—and Diffusing Capacity for Carbon Monoxide (DLCO), which measures how well oxygen transfers from your lungs into your blood [4][5]. DLCO can be influenced by other factors, such as anemia, so your doctor will interpret it in context.
- High-Resolution Computed Tomography (HRCT): A detailed chest scan that takes cross-sectional pictures of your lungs to look for scarring [4].
Pulmonary Arterial Hypertension (PAH)
PAH is high blood pressure in the arteries of your lungs, which strains the right side of your heart. To screen for PAH, doctors use:
- Echocardiogram: An ultrasound of the heart that takes about 30 to 45 minutes. It estimates the pressure in your pulmonary arteries and checks how well your right ventricle is pumping [2][6]. Importantly, an echocardiogram only estimates risk; it cannot definitively diagnose PAH, and a normal result does not guarantee that early disease is entirely absent.
- BNP or NT-proBNP: These are supportive blood markers that can signal heart strain. They are interpreted alongside your age, kidney function, and symptoms, and an elevation often prompts further testing [7][8].
Routine Screening Guidelines: What to Expect
Baseline Testing (When You Are Diagnosed)
When you are first diagnosed with MCTD, major respiratory guidelines (such as those from the ACR/CHEST) conditionally recommend a baseline PFT (including DLCO) and an HRCT scan to check for underlying ILD [4]. However, your doctor will individualize the decision for an HRCT based on your symptoms and PFT results, balancing the need for information against radiation exposure. A baseline echocardiogram is also frequently performed to evaluate your initial heart function and pulmonary pressures [2].
Follow-Up Intervals
Because MCTD guidelines do not dictate a universal timeline, follow-up depends on your risk factors [1]. The table below provides examples of how testing might be scheduled, though your care team will make the final decision:
| Clinical Situation | Tests Commonly Considered | Example Monitoring Interval |
|---|---|---|
| “Scleroderma-like” features (e.g., severe Raynaud’s, puffy hands, or nailfold capillary changes seen by a doctor) | Echocardiogram, PFTs (with DLCO) | Usually annual screening [2][3] |
| Established ILD or on active treatment | PFTs (FVC and DLCO) | Every 3 to 6 months while stabilizing, then less frequently [9][10] |
| Stable, lower-risk MCTD without symptoms | PFTs, Echocardiogram | Individualized (e.g., every 1 to 3 years based on risk profile) [3][4] |
Note: Routine repeat HRCT scans are not typically done on a fixed calendar; they are usually ordered only if your symptoms or PFTs change [4].
What Happens After an Abnormal Result?
If a screening test comes back abnormal, it does not necessarily mean you have severe lung or heart disease.
- A drop in PFT scores (like FVC or DLCO) will usually prompt your doctor to repeat the test to ensure it wasn’t a technical error, or order an HRCT to look closely at the lung tissue [11].
- If an echocardiogram shows high estimated pulmonary pressures or if your NT-proBNP is elevated, you will likely be referred to a specialist. The gold-standard confirmatory test for PAH is a right-heart catheterization—a procedure that directly measures the pressure inside your heart and lungs [8][7].
When Should Testing Be Done Sooner?
Because lung and heart complications in MCTD can develop quietly, you should not wait for your next scheduled appointment if your symptoms change [12].
Contact your doctor for an earlier evaluation if you experience:
- New or worsening shortness of breath during daily activities [13].
- A persistent, unexplained cough [14].
- Decreased exercise tolerance (feeling fatigued or winded doing tasks that used to be easy) [15].
- Unexplained swelling in your legs or ankles, or feeling faint or dizzy [2].
A note on home pulse oximeters: While some patients track their oxygen levels at home, MCTD patients often have Raynaud’s phenomenon or poor circulation in their hands, which can make finger pulse oximeters highly inaccurate. Do not rely solely on these devices to determine if you need medical care.
🚨 MEDICAL EMERGENCY WARNING 🚨
Do not wait for a scheduled appointment or a callback if you experience sudden, severe shortness of breath, chest pain, fainting, blue lips, or coughing up blood. These are medical emergencies (potentially indicating a pulmonary embolism or severe heart strain) and require you to call 911 or go to the nearest emergency department immediately [15].
Common questions in this guide
How often should I have PFTs and echocardiograms if I have MCTD?
What tests are usually done when MCTD is first diagnosed?
If I have MCTD-related interstitial lung disease, how often will my PFTs be repeated?
Can a normal echocardiogram rule out pulmonary arterial hypertension?
What symptoms mean I should contact my MCTD doctor before my next test?
What happens if my PFT or echocardiogram is abnormal?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my specific MCTD symptoms and antibodies, do I fall into a higher-risk category that requires annual echocardiograms and PFTs?
- 2.What specific changes in my daily symptoms should prompt me to call you for an earlier lung or heart test?
- 3.If my PFTs show a drop in my DLCO or FVC, what is our next step for evaluating it?
- 4.Do you check biomarkers like BNP or NT-proBNP during my routine blood work, and how do you interpret them for me?
- 5.Given my baseline test results, what exact timeline do you recommend for my next set of screenings?
- 6.What is the plan if an echocardiogram suggests elevated pulmonary pressures? Will I be referred for a right-heart catheterization?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (15)
- 1
ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease.
Antoniou KM, Distler O, Gheorghiu AM, et al.
The European respiratory journal 2026; (67(1)) doi:10.1183/13993003.02533-2024.
PMID: 40907995 - 2
CTD-PAH: an updated practical approach to screening, diagnosis, and management.
Alturaif N, Alduraibi FK
Therapeutic advances in respiratory disease 2025; (19()):17534666251385674 doi:10.1177/17534666251385674.
PMID: 41090952 - 3
Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment.
Cansu DÜ, Korkmaz C
Clinical rheumatology 2023; (42(10)):2601-2610 doi:10.1007/s10067-022-06446-y.
PMID: 36396789 - 4
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Johnson SR, Bernstein EJ, Bolster MB, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2024; (76(8)):1201-1213 doi:10.1002/art.42860.
PMID: 38973714 - 5
Insights into Pulmonary Arterial Hypertension in Connective Tissue Diseases.
Grygiel-Górniak B, Lucki M, Daroszewski P, Lucka E
Journal of clinical medicine 2025; (14(13)) doi:10.3390/jcm14134742.
PMID: 40649115 - 6
Current landscape for connective tissue disease associated-pulmonary arterial hypertension: a focus on right ventricular adaptation and failure.
Wu Q, Ye H, Zhou Z, et al.
Future cardiology 2025; (21(10)):803-814 doi:10.1080/14796678.2025.2529696.
PMID: 40641351 - 7
Pulmonary hypertension in connective tissue diseases: What every CTD specialist should know - but is afraid to ask!
Sanges S, Sobanski V, Lamblin N, et al.
La Revue de medecine interne 2024; (45(1)):26-40 doi:10.1016/j.revmed.2023.10.450.
PMID: 37925256 - 8
Screening for pulmonary arterial hypertension in systemic sclerosis.
Weatherald J, Montani D, Jevnikar M, et al.
European respiratory review : an official journal of the European Respiratory Society 2019; (28(153)) doi:10.1183/16000617.0023-2019.
PMID: 31366460 - 9
Relationship between anxiety and depression, dyspnea severity, and pulmonary function in connective tissue disease-associated interstitial lung disease.
Zhu ZJ, Liu KL, Qu HR
World journal of psychiatry 2025; (15(12)):110916 doi:10.5498/wjp.v15.i12.110916.
PMID: 41357912 - 10
Treatment with nintedanib is as effective and safe in patients with other connective tissue diseases (CTDs)-interstitial lung disease (ILD) as in patients with systemic sclerosis-ILD: A multicenter retrospective study.
Mısırcı S, Ekin A, Yağız B, et al.
Clinical rheumatology 2025; (44(3)):1187-1195 doi:10.1007/s10067-025-07323-0.
PMID: 39920562 - 11
Quantitative Phase-resolved Functional Lung MRI Prediction of Disease Progression in Connective Tissue Disease-associated Interstitial Lung Disease.
Ouyang T, Liu Q, Zhang H, et al.
Radiology 2026; (319(1)):e253337 doi:10.1148/radiol.253337.
PMID: 42048592 - 12
Mixed Connective Tissue Disease: The Two Cases Representing the Range of this Illness.
Parrey AH, Koka M, Ismail M
Current rheumatology reviews 2024; (20(5)):569-573 doi:10.2174/0115733971263972231124111042.
PMID: 38314593 - 13
CT predictors of outcomes in patients with connective tissue disease and progressive lung fibrosis.
Shou AY, Salvatore MM
Clinical imaging 2023; (94()):42-49 doi:10.1016/j.clinimag.2022.11.022.
PMID: 36493681 - 14
Interstitial Lung Disease in Patients with Mixed Connective Tissue Disease: A Retrospective Study.
Shan X, Ge Y
International journal of general medicine 2024; (17()):2091-2099 doi:10.2147/IJGM.S464704.
PMID: 38766599 - 15
Pulmonary thromboembolism as an atypical manifestation of mixed connective tissue disease in a young man: A case report.
Wang C, Cui X, Jin J
The Journal of international medical research 2025; (53(11)):3000605251397846 doi:10.1177/03000605251397846.
PMID: 41290201
This page explains how clinicians may schedule PFTs and echocardiograms for people with MCTD; it is for education and does not replace medical advice. Your rheumatologist or pulmonologist should set the timing based on your symptoms, test results, and risk factors.
Get notified when new evidence is published on Mixed connective tissue disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.